NRXP · NRX Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$2.54
-0.01 (-0.39%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 16, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least *twelve* months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Nov 16, 2026
Market Cap
$113.04M
Shares
44.33M
Volume · Nov 19
1.4M
Avg daily vol (3M)
1.06M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
NRX Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for NRX Pharmaceuticals, Inc. (NRXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-17
NRX Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
Confident tone
Revenue
$1.16M
▲ 378.9% YoY Gross margin
24.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-10-30
NRX Pharmaceuticals, Inc. (NRXP) October 30, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
NRX Pharmaceuticals, Inc. (NRXP) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-17
NRX Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
Confident tone
ALS program (GinEuro / GNK-301)
SPARC-TMS trial with DARPA/military
Preservative-free ketamine ANDA progress
Revenue
$1.10M
Gross margin
38.7%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
NRX Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Confident tone
NRX-101 and MIND-1 Trial
NRX-100 NDA and Regulatory Pathway
Ketafree / Preservative-Free Ketamine Approval
Revenue
$1.07M
Gross margin
40.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
NRX Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
Confident tone
FDA engagement and regulatory designations
NRX100 NDA and real-world evidence pathway
Hope Therapeutics subsidiary and clinic network
Revenue
$983,000*
Gross margin
58.5%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-17
NRX Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript
Positive tone
ONE-D protocol / TMS + DCS
HOPE Therapeutics clinic network
Manufacturing and supply (Blow-Fill-Seal)
Revenue
$242,000
Gross margin
59.9%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
NRX Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript
Confident tone
NRX100 ketamine regulatory progress
Hope Therapeutics clinic subsidiary
Balance sheet and financing
Revenue
$0
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-31
NRX Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
Confident tone
NRX-100 NDA and regulatory progress
NRX-101 oral combination for suicidality
HOPE Therapeutics clinic network
Revenue
$0
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
NRX Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript
Confident tone
HOPE Therapeutics Clinic Roll-Up
NRX-101 Bipolar Depression
NRX-100 Preservative-Free Ketamine NDA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-15
NRX Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
Confident tone
NRX-101 oral treatment for suicidal bipolar depression
Suicidality public health mission
Hope Therapeutics clinic acquisitions
Revenue
$0
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
NRX Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
Confident tone
NDA filings for NRX-100 and NRX-101
NRX-101 differentiation on safety (akathisia/suicidality)
HOPE Therapeutics clinic roll-up
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-16
NRX Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
Confident tone
NRX-101 in bipolar depression / akathisia
HTX-100 (IV ketamine) for suicidal depression
Regulatory and FDA pathway
Diluted EPS
$-0.74
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-04-02
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
Confident tone
Hope Therapeutics and IV ketamine
NRX-101 bipolar depression trial and Alvogen partnership
Chronic pain and PTSD indications
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Call Transcript
Diluted EPS
$-1.20
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q1 2023 Earnings Call Transcript
Diluted EPS
$-1.66
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
NRX Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.40
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q1 2022 Earnings Call Transcript
Diluted EPS
$-2.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q3 2021 Earnings Call Transcript
Diluted EPS
$-7.20
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2021 Earnings Call Transcript
Diluted EPS
$-4.10
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 webcasts
Key facts
CIK
1719406
CUSIP
629444209
13F (30d)
53 filings
49 filers
Visit website
Investor relations